Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Recruiting 3Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Metastatic Bladder Urothelial Carcinoma 1Lymphoma 1Kidney Failure, Chronic 1Extensive Stage Small Cell Lung Carcinoma 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

pembrolizumab 9Paclitaxel 9Doxorubicin 6Cyclophosphamide 6Carboplatin 5130-nm albumin-bound paclitaxel 5durvalumab 3yeast-CEA vaccine 2talazoparib 2sacituzumab govitecan 2olaparib 2glembatumumab vedotin 2avelumab 2Taxes 2Radiotherapy 2Leucovorin 2Fluorouracil 2Cisplatin 2Capecitabine 2Biopsy 2Albumin-Bound Paclitaxel 2ALT-803 2zimberelimab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab duocarmazine 1tislelizumab 1taxane 1sabizabulin 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × Immunoglobulin G × Clear all
NCT03644589 2019-04-26

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

University of Washington

Phase 2 Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡